Marie-Odile Habert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6089975/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device. Alzheimer's Research and Therapy, 2022, 14, 40.	6.2	30
2	Association of <i>APOE</i> -Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults. Neurology, 2022, 99, .	1.1	6
3	Multimodal FDG-PET and EEG assessment improves diagnosis and prognostication of disorders of consciousness. Neurolmage: Clinical, 2021, 30, 102601.	2.7	29
4	Anomaly detection for the individual analysis of brain PET images. Journal of Medical Imaging, 2021, 8, 024003.	1.5	6
5	The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease. Brain, 2021, 144, 3114-3125.	7.6	65
6	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurology, The, 2021, 20, 484-496.	10.2	396
7	Diabetes Mellitus and Cognition. Neurology, 2021, 97, e836-e848.	1.1	23
8	A machine learning approach to screen for preclinical Alzheimer's disease. Neurobiology of Aging, 2021, 105, 205-216.	3.1	18
9	Primary progressive aphasias associated with C9orf72 expansions: Another side of the story. Cortex, 2021, 145, 145-159.	2.4	9
10	Association of plasma Aβ40/Aβ42 ratio and brain Aβ accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. Neurobiology of Aging, 2021, 107, 57-69.	3.1	5
11	Dopamine denervation in the functional territories of the striatum: a new MR and atlas-based 123I-FP-CIT SPECT quantification method. Journal of Neural Transmission, 2021, 128, 1841-1852.	2.8	3
12	Recommendations of the International Working Group for the clinical diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	1
13	Importance, limits and caveats of the use of "disorders of consciousness―to theorize consciousness . Neuroscience of Consciousness, 2021, 2021, niab048.	2.6	11
14	Clinical diagnosis of Alzheimer's disease: Recommendations of the International Working Group (IWG). Alzheimer's and Dementia, 2021, 17, .	0.8	3
15	Lossâ€ofâ€Function Mutations in <i>NR4A2</i> Cause Dopaâ€Responsive Dystonia Parkinsonism. Movement Disorders, 2020, 35, 880-885.	3.9	22
16	Functional brain connectome in posterior cortical atrophy. NeuroImage: Clinical, 2020, 25, 102100.	2.7	16
17	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 2020, 94, e30-e41.	1.1	20
18	ZTE MR-based attenuation correction in brain FDG-PET/MR: performance in patients with cognitive impairment. European Radiology, 2020, 30, 1770-1779.	4.5	18

#	Article	IF	CITATIONS
19	Pathophysiology of gait disorders induced by bilateral globus pallidus interna stimulation in dystonia. Brain, 2020, 143, e3-e3.	7.6	7
20	Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD. Alzheimer's Research and Therapy, 2020, 12, 129.	6.2	18
21	Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	3.1	18
22	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. Neurobiology of Aging, 2020, 90, 43-59.	3.1	30
23	Contribution of PET-MRI in brain diseases in clinical practice. Current Opinion in Neurology, 2020, 33, 430-438.	3.6	10
24	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. Alzheimer's Research and Therapy, 2020, 12, 147.	6.2	23
25	Association of plasma YKLâ€40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e041753.	0.8	Ο
26	Aging and sex impact plasma NFL and tâ€Tau trajectories in individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e041792.	0.8	2
27	Dementia with Lewy bodies: Characteristics of the prodromal stage in a nationwide longitudinal cohort. Alzheimer's and Dementia, 2020, 16, e041858.	0.8	Ο
28	Occupational burnoutâ€like syndrome in earlyâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e041999.	0.8	1
29	Predicting factors of cognitive progression in preclinical AD: A fiveâ€year followâ€up of the insightâ€study. Alzheimer's and Dementia, 2020, 16, e042896.	0.8	0
30	Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage. Alzheimer's and Dementia, 2020, 16, e045832.	0.8	0
31	Use of FDC-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study. Journal of Neuro-Oncology, 2020, 148, 343-352.	2.9	15
32	Habituation of auditory startle reflex is a new sign of minimally conscious state. Brain, 2020, 143, 2154-2172.	7.6	28
33	Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations. Parkinsonism and Related Disorders, 2020, 80, 73-81.	2.2	13
34	Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimer's disease: the INSIGHT-preAD Study. Sleep, 2019, 42, .	1.1	32
35	Attenuation correction using 3D deep convolutional neural network for brain 18F-FDG PET/MR: Comparison with Atlas, ZTE and CT based attenuation correction. PLoS ONE, 2019, 14, e0223141.	2.5	40
36	Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer's disease: The INSIGHT-preAD study. EBioMedicine, 2019, 47, 518-528.	6.1	36

#	Article	IF	CITATIONS
37	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging, 2019, 83, 42-53.	3.1	48
38	Focal status epilepticus in anti-Hu encephalitis. Autoimmunity Reviews, 2019, 18, 102388.	5.8	5
39	Tribute to Anne Bertrand (1978–2018): Neuroradiologist, scientist, teacher and friend. Journal of Neuroradiology, 2019, 46, 155-159.	1.1	0
40	EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. Brain, 2019, 142, 2096-2112.	7.6	131
41	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 764-775.	0.8	122
42	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 940-950.	0.8	43
43	Testing the therapeutic effects of transcranial direct current stimulation (tDCS) in semantic dementia: a double blind, sham controlled, randomized clinical trial. Trials, 2019, 20, 632.	1.6	9
44	FDG PET/MRI Findings Pointing Toward a Gayet-Wernicke Encephalopathy. Clinical Nuclear Medicine, 2019, 44, e456-e457.	1.3	2
45	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid-β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. Radiology, 2019, 290, 167-176.	7.3	30
46	Title is missing!. , 2019, 14, e0223141.		0
47	Title is missing!. , 2019, 14, e0223141.		0
48	Title is missing!. , 2019, 14, e0223141.		0
49	Title is missing!. , 2019, 14, e0223141.		Ο
50	Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurology, The, 2018, 17, 335-346.	10.2	161
51	Early Cognitive, Structural, and Microstructural Changes in Presymptomatic <i>C9orf72</i> Carriers Younger Than 40 Years. JAMA Neurology, 2018, 75, 236.	9.0	108
52	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease, 2018, 64, S47-S105.	2.6	122
53	A New Fire Hazard for MR Imaging Systems: Blankets—Case Report. Radiology, 2018, 286, 568-570.	7.3	7
54	No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. NeuroImage: Clinical, 2018, 17, 435-443.	2.7	19

#	Article	IF	CITATIONS
55	Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. Annals of Nuclear Medicine, 2018, 32, 75-86.	2.2	45
56	Survival and consciousness recovery are better in the minimally conscious state than in the vegetative state. Brain Injury, 2018, 32, 72-77.	1.2	61
57	An Automated Pipeline for the Analysis of PET Data on the Cortical Surface. Frontiers in Neuroinformatics, 2018, 12, 94.	2.5	16
58	Structural, Microstructural, and Metabolic Alterations in Primary Progressive Aphasia Variants. Frontiers in Neurology, 2018, 9, 766.	2.4	33
59	Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers. NeuroImage: Clinical, 2018, 20, 1018-1025.	2.7	21
60	Multimorbidity Is Associated with Preclinical Alzheimer's Disease Neuroimaging Biomarkers. Dementia and Geriatric Cognitive Disorders, 2018, 45, 272-281.	1.5	18
61	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience, 2018, 10, 67.	3.4	29
62	Reproducible evaluation of classification methods in Alzheimer's disease: Framework and application to MRI and PET data. NeuroImage, 2018, 183, 504-521.	4.2	132
63	Unexpected good outcome in severe cerebral fat embolism syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 988-995.	3.7	10
64	[P3–198]: PREDICTION PERFORMANCE OF ALPHAâ€SYNUCLEIN PROTEIN IN PRECLINICAL SUBJECTIVE MEMOR COMPLAINERS STRATIFIED BY AD BIOMARKERS: THE INSIGHTâ€PRE AD STUDY. Alzheimer's and Dementia, 2017, 13, P1011.	Y 0.8	0
65	Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. Alzheimer's Research and Therapy, 2017, 9, 67.	6.2	45
66	Cortical amyloid accumulation is associated with alterations of structural integrity in older people with subjective memory complaints. Neurobiology of Aging, 2017, 57, 143-152.	3.1	18
67	Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 753-762.	2.6	36
68	Bee Venom for the Treatment of Parkinson Disease – A Randomized Controlled Clinical Trial. PLoS ONE, 2016, 11, e0158235.	2.5	39
69	CATI: A Large Distributed Infrastructure for the Neuroimaging of Cohorts. Neuroinformatics, 2016, 14, 253-264.	2.8	33
70	Optimization of brain PET imaging for a multicentre trial: the French CATI experience. EJNMMI Physics, 2016, 3, 6.	2.7	22
71	Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain, 2016, 139, 1079-1093.	7.6	157
72	Lateral Temporal Lobe: An Early Imaging Marker of the Presymptomatic GRN Disease?. Journal of Alzheimer's Disease, 2015, 47, 751-759.	2.6	34

#	Article	IF	CITATIONS
73	Progressive Supranuclear Palsy Syndrome and Semantic Dementia in Neuropathologically Proven Lewy Body Disease: A Report of Two Cases. Journal of Alzheimer's Disease, 2015, 47, 95-101.	2.6	5
74	Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 471-476.	2.2	17
75	Safety profile of intracranial electrode implantation for video-EEG recordings in drug-resistant focal epilepsy. Journal of Neurology, 2015, 262, 2699-2712.	3.6	41
76	Feeling unreal: a functional imaging study in patients with Kleine-Levin syndrome. Brain, 2014, 137, 2077-2087.	7.6	70
77	Characteristics of the default mode functional connectivity in normal ageing and Alzheimer's disease using resting state fMRI with a combined approach of entropy-based and graph theoretical measurements. NeuroImage, 2014, 101, 778-786.	4.2	89
78	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
79	Visuospatial deficits and hemispheric perfusion asymmetries in posterior cortical atrophy. Cortex, 2013, 49, 940-947.	2.4	17
80	Frontal presentation of Alzheimer's disease: A series of patients with biological evidence by CSF biomarkers. Dementia E Neuropsychologia, 2013, 7, 66-74.	0.8	29
81	Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer's disease using conjoint univariate and independent component analyses. NeuroImage, 2012, 63, 936-946.	4.2	87
82	Visuospatial deficits in posterior cortical atrophy: structural and functional correlates. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 860-863.	1.9	23
83	Generalized dystonia, athetosis, and parkinsonism associated with <i>FOXG1</i> mutation. Movement Disorders, 2012, 27, 160-162.	3.9	7
84	Automatic classification of patients with Alzheimer's disease from structural MRI: A comparison of ten methods using the ADNI database. NeuroImage, 2011, 56, 766-781.	4.2	834
85	Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment. Neurobiology of Aging, 2011, 32, 15-23.	3.1	80
86	CT Nonuniform Attenuation and TEW Scatter Corrections in Brain Tc-99m ECD SPECT. Clinical Nuclear Medicine, 2011, 36, 665-668.	1.3	8
87	Similar amyloid-Î ² burden in posterior cortical atrophy and Alzheimer's disease. Brain, 2011, 134, 2036-2043.	7.6	121
88	Neural correlates of cognitive impairment in posterior cortical atrophy. Brain, 2011, 134, 1464-1478.	7.6	155
89	Poor creativity in frontotemporal dementia: A window into the neural bases of the creative mind. Neuropsychologia, 2010, 48, 3733-3742.	1.6	103
90	Differential automatic diagnosis between Alzheimer's disease and frontotemporal dementia based on perfusion SPECT images. Artificial Intelligence in Medicine, 2009, 47, 147-158.	6.5	43

#	Article	IF	CITATIONS
91	"What is it?―A functional MRI and SPECT study of ictal speech in a second language. Epilepsy and Behavior, 2009, 14, 396-399.	1.7	8
92	Frontal Assessment Battery is a marker of dorsolateral and medial frontal functions: A SPECT study in frontotemporal dementia. Journal of the Neurological Sciences, 2008, 273, 84-87.	0.6	71
93	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain, 2008, 131, 732-746.	7.6	331
94	Brain perfusion imaging in amyotrophic lateral sclerosis: Extent of cortical changes according to the severity and topography of motor impairment. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 9-15.	2.1	24
95	Validation of a Standardized Normalization Template for Statistical Parametric Mapping Analysis of 1231-FP-CIT Images. Journal of Nuclear Medicine, 2007, 48, 1459-1467.	5.0	57
96	A dent in the head. Lancet, The, 2007, 370, 1854.	13.7	1
97	Functional Imaging of Cataplexy During Status Cataplecticus. Sleep, 2007, 30, 153-156.	1.1	38
98	Ictal Brain Hyperperfusion Contralateral to Seizure Onset: The SPECT Mirror Image. Epilepsia, 2006, 47, 123-133.	5.1	51
99	Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain, 2006, 129, 3051-3065.	7.6	158
100	Effortless control: executive attention and conscious feeling of mental effort are dissociable. Neuropsychologia, 2005, 43, 1318-1328.	1.6	158
101	Transient Improvement of Aphasia with Zolpidem. New England Journal of Medicine, 2004, 350, 949-950.	27.0	89
102	Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies. Brain, 2003, 126, 2761-2772.	7.6	212
103	Proportional anatomical stereotactic atlas for visual interpretation of brain SPET perfusion images. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 871-877.	2.1	6